AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01900808 — intervention group
Intervention type: DEVICE
Intervention: Experienced operator with XL probe.
Description: Experienced operator with XL probe: non-drug intervention, longitudinal comparator.
Study NCT02477189 — intervention group
Intervention type: PROCEDURE
Intervention: Silicone Block
Study NCT05820984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPIRIT checklist plus usual practice
Description: Peer reviewer will be reminded of the following 10 CONSORT items (including a short description):~Outcomes (12) Sample size (14) Recruitment (15) Allocation implementation (16 c) Blinding (17 a) Data collection methods (18 a) Data collection methods - retention (18 b) Statistical methods (20 a) Population analysed (20 c) Access to data (29)
Study NCT05820984 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual practice
Description: Peer review as it is usual practice at the journal
Study NCT01930721 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: episiotomy
Description: incision angle of episiotomy will be 60 degrees.
Study NCT01930721 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: episiotomy
Description: incision angle of episiotomy will be 40 degree before cutting.
Study NCT03811301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrainConnexion
Description: A 4.4mm by 4.2mm electrode array is placed onto the surface of the motor cortex which is then connected to a miniaturized neural recording microsystem that transmits signals wirelessly to control an external assistive device. Neural signals are recorded at least once every week for 12 months or longer.
Study NCT03203434 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary volatile organic compound analysis
Study NCT00776646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrochlorothiazide 50 mg tablet
Study NCT01985425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg
Study NCT01985425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Colchicine
Study NCT04341948 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SPRINT Peripheral Nerve Stimulation (PNS) System
Description: The SPRINT System delivers mild electrical stimulation to nerves in the affected limb. The SPRINT System includes two small wires (called Leads) that are placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator).
Study NCT04341948 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SPRINT Peripheral Nerve Stimulation (PNS) System
Description: The SPRINT System delivers mild electrical stimulation to nerves in the affected limb. The SPRINT System includes two small wires (called Leads) that are placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator).
Study NCT04649177 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ocular surface optical coherence tomography
Description: EYEdeal Scanning technology enables rapid measurement of the corneal and scleral topography which provides data for an automated sequence to fit PROSE devices
Study NCT02335593 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Sulphate
Description: Zinc Sulphate Hard Gel capsules 110mg
Study NCT02335593 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corn Starch filled Hard Gel Capsules
Description: Corn Starch filled Hard Gel Capsules
Study NCT02335593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa 2000-4000 IU solution for injection
Description: Epoetin alfa 2000-4000 IU solution for injection
Study NCT02335593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 2000-4000 IU solution for injection
Description: Epoetin alfa 2000-4000 IU solution for injection
Study NCT02335593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Hydroxide Saccharate Complex Solution for injection
Description: Iron Hydroxide Saccharate Complex Solution for injection
Study NCT02335593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Hydroxide Saccharate Complex Solution for injection
Description: Iron Hydroxide Saccharate Complex Solution for injection
Study NCT00474617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Study NCT00474617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocurium
Description: intravenous (IV) single bolus dose of 0.6 mg.kg-1
Study NCT06480149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMALC
Description: Classical shoulder massage was applied to both shoulders of the patient for 10-15 minutes each.
Study NCT06480149 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no application
Description: In the control group, there was no massage application and only pain and sleep quality were evaluated.
Study NCT01502163 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermoflect [TM] passive insulation
Description: passive insulation in the preoperative phase, befor induction of anesthesia
Study NCT01502163 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active prewarming (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL)
Description: Prewarming Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL before induction of anesthesia
Study NCT01115374 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual lymphatic drainage
Description: Application of manual lymphatic drainage (one session every work day during two weeks, total 10 sessions)
Study NCT01115374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low frequency sound waves
Description: Application of low frequency sound waves (one session every work day during two weeks, total 10 sessions)
Study NCT03723746 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo in all cohorts.
Study NCT02264132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole ER tablet
Study NCT02264132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole IR tablet
Study NCT01750008 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Global Fibroid Ablation
Study NCT04616222 — intervention group
Intervention type: DRUG
Intervention: CELSIOR® group
Description: Patient who received Celsior® during their transposition of the great vessels surgery according to the routine care.
Study NCT04616222 — intervention group
Intervention type: DRUG
Intervention: Saint-Thomas group
Description: Patient who received Saint-Thomas during their transposition of the great vessels surgery according to the routine care.
Study NCT04164420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral neuromuscular training and orofacial sensory-vibration
Description: Oral neuromuscular training is performed by using an oral device. The device is placed pre-dentally behind closed lips, and the participant is sitting in an up-right position. The participant is the instructed to hold the device against a gradually-increasing horizontal pulling force for 5-10 s, whilst trying to resist the force by tightening the lips and pressing the head backward against a head rest.
Study NCT01029639 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)
Description: Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
Study NCT02493556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LLLT before muscle damage
Study NCT02493556 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo LLLT before muscle damage
Study NCT02493556 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LLLT after muscle damage
Study NCT02493556 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo LLLT after muscle damage
Study NCT03326856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin, Type A
Description: topical liniment
Study NCT04164420 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Orofacial sensory-vibration stimulation
Description: All participants in the control group is given orofacial sensory-vibration stimulation by using an electrical toothbrush. Instructions is given on how to stimulate the buccinator mechanism, lips, external floor, and the tongue three times daily before a meal.
Study NCT01750008 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Myomectomy
Study NCT02970279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Activation Group (BAG) Psychotherapy
Description: Behavioural activation (BA) is a psychotherapy intervention based on behaviour theory and operant conditioning. It teaches patients to reduce avoidant depressive behaviours and in turn increase the positive reinforcement they receive from their environment for non-depressive behaviours through the use of activity scheduling and pleasant events. For the trial, BA will be delivered in a group format (BAG) and facilitated by two therapists. BAG treatment will consist of eight weekly sessions, lasting two hours and will follow a manualised treatment protocol. Each session will be based on a different topic relevant to the principles of BA and patients will be given between session work to complete to encourage increased participation in rewarding personally meaningful activities.
Study NCT01428180 — intervention group
Intervention type: DRUG
Intervention: Indomethacin
Description: 3 doses of 0,2mg/kg every 12h (first week of life) or every 8h (after first week of life)
Study NCT01428180 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical Ligation
Description: In nonresponders to medical treatment with persistent hemodynamically relevant patent ductus arteriosus surgical ligation is performed.
Study NCT01428180 — intervention group
Intervention type: DRUG
Intervention: Ibuprofen
Description: 3 doses every 24h; first dose 10mg/kg, second and third dose 5mg/kg
Study NCT02206555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emtricitabine/tenofovir disoproxil fumarate
Study NCT03837561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cunox
Description: Inject 4 Units (0.1 mL) of reconstituted investigational product or the comparator intramuscularly into each of 5 sites, 2 in each corrugator muscle and 1 in the procerus muscle for a total dose of 20 Units.
Study NCT03837561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: Inject 4 Units (0.1 mL) of reconstituted investigational product or the comparator intramuscularly into each of 5 sites, 2 in each corrugator muscle and 1 in the procerus muscle for a total dose of 20 Units.
Study NCT03337100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Co-Dispensing
Description: Implementation of a naloxone co-dispensing pharmacy program.~The intent of this program is to provide patients prescribed chronic opioid therapy naloxone under the terms of a standing order for potential opioid overdose reversal. Prior to implementing the program, a naloxone standing order will be implemented and pharmacy operational staff will provide training to pharmacy staff about the standing order and a naloxone co-dispensing protocol. Under a co-dispensing protocol, pharmacy staff members will identify opioid prescriptions meeting criteria for co-dispensing, prepare naloxone fills, offer patients naloxone, and provide counseling on its use.
Study NCT01807897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: Nocturnal continuous positive airway pressure, titrated to minimize apnea-hypopnea index
Study NCT01807897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nocturnal supplemental oxygen
Description: Nocturnal supplemental oxygen, titrated to 2-4 liters/minute with target of eliminating nocturnal hypoxemia
Study NCT01807897 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle and Sleep Education
Description: A 60-minute educational intervention with slide show and printed materials, educating the patient in healthy sleep habits and heart-healthy lifestyle
Study NCT04243733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CEM and MTA
Description: Pulpotomy agent
Study NCT04243733 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CEM and MTA
Description: Pulpotomy agent
Study NCT04243733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MTA and CEM
Description: Pulpotomy agent
Study NCT04243733 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MTA and CEM
Description: Pulpotomy agent
Study NCT03989401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimedia video health education
Description: The experimental group conducted multimedia video education while admission.
Study NCT01807897 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy Lifestyle and Sleep Education
Description: A 60-minute educational intervention with slide show and printed materials, educating the patient in healthy sleep habits and heart-healthy lifestyle
Study NCT02624427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of intraocular pressure (IOP)
Description: Measurement of IOP with the following devices: (1) Goldmann tonometer, (2) Dynamic Contour tonometer, and (3) Corvis ST tonometer
Study NCT02624427 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of intraocular pressure (IOP)
Description: Measurement of IOP with the following devices: (1) Goldmann tonometer, (2) Dynamic Contour tonometer, and (3) Corvis ST tonometer
Study NCT04544579 — intervention group
Intervention type: DEVICE
Intervention: Stent grafts anchored in different areas
Description: Endovascular repair of ascending aortic dissection patients with stent grafts anchored in different areas
Study NCT03893162 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic
Description: The intervention in this study is a multi-strain probiotic which contains:~Bacillus subtilis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus delbrueckii ssp. bulgaricus, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus helveticus, Lactobacillus salivarius, Lactococcus lactis ssp. lactis, Streptococcus thermophilus.~Each capsule contains minimum 2 billion live microorganisms per capsule, equivalent to 10 billion live microorganisms per gram.
Study NCT03893162 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visually identical capsules in identical packaging containing no active bacteria.
Study NCT01054001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil 100mg
Description: sildenafil 100mg per oral twice a week
Study NCT02846649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PIER
Description: Daily text message queries with tailored support
Study NCT00924508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hydrogel patch
Description: occlusion of eczema with a hydrogel patch composed of an adhesive, thin, flexible, hydrogel layer on an impermeable urethane surface.
Study NCT00924508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone (TAC) 0.1% cream
Description: Triamcinolone Acetonide (triamcinolone acetonide cream) is a topical corticosteroid used as anti-inflammatory and antipruritic agent. Each gram of TAC Cream USP, 0.1% contains 1 mg Triamcinolone Acetonide (triamcinolone acetonide cream) in a cream base consisting of cetyl alcohol, glyceryl monostearate, cetyl esters wax, isopropyl palmitate, polysorbate-60, polysorbate-80, propylene glycol and purified water.
Study NCT03654885 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XEN-45 Gel Stent
Description: XEN-45 gel stent device implant
Study NCT03654885 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy
Description: Trabeculectomy surgery
Study NCT03989362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vopratelimab
Description: Specified dose on specified days
Study NCT03989362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT02289872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TruView PCD Video laryngoscope
Description: Video-Laryngoscopy
Study NCT01106508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEQ506
Study NCT04508153 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Leva Pelvic Digital Health System
Description: Pelvic floor muscle training using the pelvic digital health system to treat pelvic floor disorders, specifically stress urinary incontinence.
Study NCT04508153 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Kegel exercises
Description: Pelvic floor muscle training (PFMT), commonly referred to as Kegel exercises, is a first line conservative treatment for pelvic floor disorders, specifically stress urinary incontinence (SUI) or stress-predominant mixed urinary incontinence (SMUI).
Study NCT02227394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z7200
Description: Total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01).~At visit 2 or 3 (cross-over design)
Study NCT02227394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort® Turbohaler®
Description: Total dose budesonide/formoterol is 320 mcg/9 mcg. At visit 2 or 3 (cross-over design)
Study NCT04558359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: These patients will receive standard of care treatment. Plasma renin levels and biomarkers of renal function will be measured.
Study NCT04558359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: These patients will receive angiotensin II in addition to standard of care treatment. Plasma renin levels and biomarkers of renal function will be measured.
Study NCT03291990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 5 fraction hypofractionated stereotactic radiosurgery along with standard temozolomide
Study NCT00707954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-7284
Description: Patients will receive single ascending dose of TA-7284 in each step (4 doses planned: 25, 100, 200 and 400 mg), once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)
Study NCT00707954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of TA-7284
Description: Patients will receive placebo tablets in each step, once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)
Study NCT04159792 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: No intervention
Study NCT03137498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine 1.5mg/kg IVPB in 50ml normal saline over 10 minutes x 1dose
Study NCT03137498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Ketorolac 30mg (1ml) intravenous push injection x 1dose
Study NCT03086902 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation Catheter
Description: Ablation of PVC with RF energy
Study NCT03244111 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: simple memory tool
Description: The goals may be implemented using the simple memory tool. Simple memory tool involves using materials such as checklists or diaries to assist with memory.
Study NCT03086902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryo Ablation catheter
Description: Ablation pf PVC with Cryo enerygy
Study NCT03502902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC 68498
Description: HEC68498 is a potent,highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR). It has shown good activity against fibrosis and inflammation in vitro and in vivo, with a lower effective dose and better efficacy than pirfenidone and nintedanib.
Study NCT00367952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apricitabine
Description: 800mg apricitabine twice daily orally for 96 weeks
Study NCT01087086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crononutrition
Description: After the recruitment and selection of the study participants, the study will consists of a 2-month nutritional intervention (Crononutrition versus AHA) followed by second 6-month period (autonomy phase) in which the subjects of the study will continue with their ruled dietary patterns, but without any dietary or psychological support.
Study NCT01087086 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: American Heart Association
Description: After the recruitment and selection of the study participants, the study will consists of a 2-month nutritional intervention (Crononutrition versus AHA) followed by second 6-month period (autonomy phase) in which the subjects of the study will continue with their ruled dietary patterns, but without any dietary or psychological support.
Study NCT03502902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03603106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277
Description: Part I: P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: P03277 was administered intravenously with a flow rate of 2 mL/s.